sarepta.com

GENERAL
META
HTML
LINK ANALYSIS
SERVER

Sarepta.com receives any estimated 877 unique visitors and 2,158 unique page views per day. Revenue gained from these much visits may be $1 per day from various advertising sources. The estimated worth of site is $462. Similarweb global rank is 1,464,771. Maximum no. of users comes from .

Amazon.com, Inc. is ISP, hosted on IP 54.204.43.126 in Country United States.

Website Age n/a
Alexa Rank no-data
Country United States
IP Address 54.204.43.126

META INFORMATION

Title

Sarepta Therapeutics | Biopharmaceutical Company for Rare Diseases

Description

We are focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases. Learn more about Sarepta.

Keywords

Content Type

utf-8

No	Meta Name	Value
1	viewport	width=device-width, initial-scale=1.0
2	viewport	width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=no

GENERAL HTML INFORMATION

Type	Status
HTML 5
Responsive Website

HTML SIZE INFORMATION

Text / Code Ratio 6.89 %

sarepta.com has a website text/code ratio of 6.89 %. Search engine crawlers tend to not pick up pages with inadequate content.

IMPORTANT HTML TAGS AND COUNTS

Titles

H10
H219
H30
H44
H54
H60

No	Text
1	Press releases (2)
2	Utility menu (2)
3	Regional navigation (2)
4	Main navigation (2)
5	Social links
6	We see a revolution.
7	Our scientists would disagree.
8	So neither will we.
9	Join us.
10	Sarepta’s response to covıd-19
11	An opportunity to change the face of healthcare
12	Spotlight on: development programs
13	Corporate updates
14	Follow us on social
15	Footer utility nav

No	Text
1	Exploring the potential of gene therapies for limb-girdle muscular dystrophies
2	Rna-targeted therapies: a development strategy for protein upregulation
3	A new fda-approved treatment
4	Sarepta therapeutics' presentation from the 38th annual j.p. morgan healthcare conference (2020)

No	Text
1	Some see slow and steady scientific progress.
2	Some think a cure for a rare disease is a miracle.
3	Patients can’t wait for the next breakthrough in medical research.
4	The opportunity to transform lives is breathtaking.

Text Styling

STRONG9
B0
EM0
I0
U0
CITE0

STRONG

No	Text
1	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (2)
2	Sarepta Therapeutics to Announce Second Quarter 2020 Financial Results and Recent Corporate Developments on August 5, 2020 (2)
3	Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy (2)
4	For patients in the U.S. taking an approved Sarepta therapy,
5	For partic****nts in Sarepta-sponsored clinical trials,
6	Resources for patients and caregivers

LINK ANALYSIS

Total Link Count: 113

Internal Link Count : 71

No	Text	Type
1	Newsroom	text
2	Contact Us	text
3	English	text
4	-	image
5	Newsroom	text
6	Contact Us	text
7	English	text
8	-	image
9	Our Disease Areas	text
10	Duchenne Muscular Dystrophy	text
11	Limb-girdle Muscular Dystrophy	text
12	Mucopolysaccharidosis Type IIIA	text
13	Charcot-Marie-Tooth Disease	text
14	Our Science	text
15	Gene Therapy Engine	text
16	RNA Platform	text
17	Gene Editing	text
18	Manufacturing	text
19	Strategic Partners***ps	text
20	Our Products & Pipeline	text
21	Products	text
22	Pipeline	text
23	Clinical Trials	text
24	Treatment Access	text
25	About Us	text
26	Leaders***p	text
27	Patient Advocacy	text
28	Corporate Responsibility	text
29	Grants & Giving	text
30	Global Locations	text
31	Contact Us	text
32	Join Us	text
33	-	empty
34	Learn more	text
35	Learn more here	text
36	Learn more	text
37	Learn more about working at Sarepta	text
38	Read our Company Statement	text
39	+1-888-727-3782	text
40	+1-800-690-2003	text
41	[email protected]	text
42	Learn More	text
43	View our approved products	text
44	Our Disease Areas	text
45	Duchenne Muscular Dystrophy	text
46	Limb-girdle Muscular Dystrophy	text
47	Mucopolysaccharidosis Type IIIA	text
48	Charcot-Marie-Tooth Disease	text
49	Our Science	text
50	Gene Therapy Engine	text

External Link Count : 42

No	Text	Type
1	See All	text
2	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	text
3	Sarepta Therapeutics to Announce Second Quarter 2020 Financial Results and Recent Corporate Developments on August 5, 2020	text
4	Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy	text
5	Investors	text
6	Portugues	text
7	Français	text
8	Deutsch	text
9	Italiano	text
10	j***anese	text
11	Deutsch	text
12	English	text
13	Français	text
14	Italiano	text
15	English	text
16	Investors	text
17	Portugues	text
18	Français	text
19	Deutsch	text
20	Italiano	text
21	j***anese	text
22	Deutsch	text
23	English	text
24	Français	text
25	Italiano	text
26	English	text
27	Career Opportunities	text
28	Twitter	text
29	LinkedIn	text
30	Instagram	text
31	Facebook	text
32	See All	text
33	Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	text
34	Sarepta Therapeutics to Announce Second Quarter 2020 Financial Results and Recent Corporate Developments on August 5, 2020	text
35	Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy	text
36	Read press release	text
37	View presentation (PDF)	text
38	Twitter	text
39	LinkedIn	text
40	Instagram	text
41	Facebook	text
42	Career Opportunities	text